Bruno Giethlen

This inventor holds 23 USPTO granted patents and 11 published patent applications, plus 7 CIPO patents and 11 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Ab Science, University of Southern California, Janssen Pharmaceutica Nv. Active years: 2007-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bruno Giethlen. Retrieved from https://idiyas.com/inventor/bruno-giethlen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23 (Patent Applications = 11)

% Patents Active = 52.2

CIPO Patents = 7

EPO Patents = 11 (Patent Applications = 20)

Average Co-Inventor Count = 4.5

ph-index = 7

Forward Citations = 159(Granted Patents)

Location History:

Altofr, FR (2015)
Illkirch, FR (2010 - 2018)
Altorf, FR (2007 - 2021)

Company Filing History:

University of Southern California

patents

4 out of 2,101

Janssen Pharmaceutica Nv

patents

4. 2 out of 5,383

Centre National De La Recherche Scientifique

Merck Sharp + Dohme Corp.

Eli Lilly and Company

patents

11. 1 out of 79

European Molecular Biology Laboratory

patents

12. 1 out of 181

F. Hoffmann-La Roche Ag

patents

13. 1 out of 1

Prestwick Chemical, Inc.

patent

14. 1 out of 8

Savira Pharmaceuticals Gmbh

patents

where one patent can have more than one assignee

Years Active: 2007-2021

Loading Chart...

Areas of Expertise:

Deoxyuridine Triphosphatase Inhibitors

Nicotinic Acetylcholine Receptor Modulators

Tyrosine Kinase Inhibitors

MDM2 P53 Interaction Inhibitors

Anti-Bacterial Compounds

Cyclic-Alkylamine Derivatives

Oxime Derivatives

Heteroatom Compounds

Allosteric Modulators

Aminoaryl Compounds

Thiazole Derivatives

5-HT6 Receptor Antagonists

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10889563 - Deoxyuridine triphosphatase inhibitors (2021-01-12),

2. 10457673 - Heteroatom containing deoxyuridine triphosphatase inhibitors (2019-10-29),

3. 10227326 - Deoxyuridine triphosphatase inhibitors (2019-03-12),

4. 9994518 - Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof (2018-06-12),

5. 9809571 - Deoxyuridine triphosphatase inhibitors (2017-11-07),

6. 9790214 - Heteroatom containing deoxyuridine triphosphatase inhibitors (2017-10-17),

7. 9790173 - Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof-I (2017-10-17),

8. 9434745 - 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease (2016-09-06),

9. 9062013 - Positive allosteric modulators of the α7 nicotinic acetylcholine receptor and uses thereof (2015-06-23),

10. 8993573 - 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors (2015-03-31),

11. 8962627 - Oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors (2015-02-24),

12. 8835435 - 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors (2014-09-16),

13. 8450302 - 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors (2013-05-28),

14. 8404683 - Inhibitors of the interaction between MDM2 and P53 (2013-03-26),

15. 8377961 - Cyclic-alkylamine derivatives as inhibitors of the interaction between MDM2 and P53 (2013-02-19),

Title: Bruno Giethlen: Pioneering Sustainable Solutions through Innovation

Introduction:

Bruno Giethlen, a visionary inventor hailing from Altorf, FR, has undeniably left an indelible mark on the industry with his unwavering commitment to innovation and sustainability. With 23 patents to his name, Giethlen's groundbreaking work continues to propel technological advancements towards a more sustainable future.

Latest Patents:

Giethlen's latest patents showcase his ingenuity in the realm of pharmaceuticals and cancer treatment. His inventions include Deoxyuridine triphosphatase inhibitors and Heteroatom containing deoxyuridine triphosphatase inhibitors, which offer novel approaches in combating cancer through innovative molecular structures. These patents exemplify Giethlen's dedication to pushing the boundaries of science and medicine.

Career Highlights:

Throughout his illustrious career, Bruno Giethlen has made significant contributions to esteemed institutions such as Ab Science and the University of Southern California. His relentless pursuit of excellence has led to the development of cutting-edge technologies that have the potential to revolutionize the field of pharmaceuticals.

Collaborations:

In his pursuit of innovation, Giethlen has collaborated with esteemed colleagues such as Camille Georges Wermuth and Christophe Morice. Together, they have worked tirelessly to bridge the gap between scientific research and real-world applications, paving the way for transformative solutions in the industry.

Conclusion:

Bruno Giethlen's passion for innovation and his tireless dedication to creating a sustainable world have rightfully positioned him as a trailblazer in the field of technology. His visionary approach to problem-solving and his unwavering commitment to pushing boundaries continue to inspire and shape the future of scientific advancements.

Profile summary based on public USPTO records.